Trials / Completed
CompletedNCT04521465
Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye
A Multi-Center, Single Arm, Post-Market Clinical Follow-up Study to Evaluate the Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (actual)
- Sponsor
- Novaliq GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This PMCF study is carried out following successful CE marking of NovaTears® + Omega-3 and is intended to generate systematic clinical data on the safety and performance of the device when used in accordance with the intended purpose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters) | Eye drops |
Timeline
- Start date
- 2020-11-09
- Primary completion
- 2021-02-17
- Completion
- 2021-02-17
- First posted
- 2020-08-20
- Last updated
- 2021-04-15
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04521465. Inclusion in this directory is not an endorsement.